Affordable Access

deepdyve-link
Publisher Website

Prognostic value of the metabolic bulk volume in patients with diffuse large B-cell lymphoma on baseline 18F-FDG PET-CT.

Authors
  • Delaby, Gauthier1
  • Hubaut, Marc-Antoine1
  • Morschhauser, Franck2
  • Besson, Alix1
  • Huglo, Damien1
  • Herbaux, Charles2
  • Baillet, Clio1
  • 1 Service de médecine nucléaire, Université de Lille, Lille, France. , (France)
  • 2 Service des Maladies du Sang, Université de Lille, Lille, France. , (France)
Type
Published Article
Journal
Leukemia & Lymphoma
Publisher
Informa UK (Taylor & Francis)
Publication Date
Jul 01, 2020
Volume
61
Issue
7
Pages
1584–1591
Identifiers
DOI: 10.1080/10428194.2020.1728750
PMID: 32100597
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

We retrospectively investigated the prognostic value of the metabolic bulk volume (MBV), defined as the metabolic volume of the largest lesion, in 106 patients with diffuse large B-cell lymphoma who underwent baseline 18FDG PET-CT. Semi-automatically segmented (41% SUVmax) total metabolic tumor volume (TMTV) and MBV underwent receiver operating characteristic analysis, identifying optimal thresholds of 147 cm3 for the TMTV and 41.5 cm3 for the MBV. A low TMTV and a low MBV were significantly associated with longer progression-free survival (PFS) and overall survival (OS). According to Cox multivariate analysis, the TMTV and MBV were independent predictors, respectively, for PFS (HR = 3.501), and OS (HR = 7.242). The TMTV and MBV classification were discordant in 18.9% of patients with a 5-year PFS rate of 100% for patients with low MBV/high TMTV and 74% for high MBV/low TMTV. The baseline MBV can be an efficient tool for the risk stratification of aggressive lymphoma.

Report this publication

Statistics

Seen <100 times